Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... YORK , September 2, 2014 ... Study on Membrane Technology in Pharmaceutical, Biopharma and Life ... Highest Growth by 2019" the global membrane technology market for pharmaceutical, ... million in 2014 and is expected to grow at ... reach an estimated value of USD 10,886.0 million in ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014 Orexigen ... that the U.S. Patent and Trademark Office (PTO) has ... medication being evaluated for weight loss. NB32 is a ... SR. U.S. Patent No. 8,815,889 claims methods ... and bupropion. The patent expires in 2024. If NB32 ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 ... of its 11th clinical research site: PMG Research of ... ownership and operation of the clinical research department at ... expanding PMG’s presence in eastern North Carolina. This new ... For the patients in Rocky Mount and the surrounding ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... $1,712.1 million by 2019 from $1,070.7 million in ... 2014 to 2019. The global oligonucleotide synthesis market ... services, applications, end users, and geography. The synthesized ... growth rate in the oligonucleotide synthesis market during ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... advanced tools after their brains evolved a greater capacity for ... it took early humans almost two million years to move ... used computer modelling and tiny sensors embedded in gloves to ... order to make two types of tools during the Lower ...
... 2010Scientists at the U.S. Department of Energy,s Los Alamos ... thin films capable of absorbing light and generating electric ... in the journal Chemistry of Materials, could ... "Potentially, with future refinement of this technology, windows in ...
... Colo., Nov. 3, 2010 Bolder BioTechnology, Inc. today ... $1.2 million in Qualifying Therapeutic Discovery Project Grants.  Grants ... Discovery Project Tax Credit Program, which authorized up to ... companies with 250 or fewer employees.   ...
Cached Biology Technology:Stone Age humans needed more brain power to make big leap in tool design 2Scientists produce transparent, light-harvesting material 2Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... British Columbia researchers are part of an international team ... a step they hope will lead to a universal ... conservation efforts. Barcodes based on portions of DNA ... have already emerged as a viable solution for ...
... The most comprehensive analysis yet of the genome of childhood ... the genetic blueprint, suggesting the cancer arises from just a ... Children,s Research Hospital. The research appears in the July 27 ... of Sciences . "Our data raise the ...
... BOSTONThe androgen receptor a protein ignition switch ... a master of adaptability. When drug therapy deprives the ... receptor manages to find an alternate growth route. A ... University scientists demonstrates how. The shift from androgen-dependent to ...
Cached Biology News:UBC researchers help push for standard DNA barcodes for plants 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 3Study reveals a reprogrammed role for the androgen receptor 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: